The KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to identify mutations in the KCNC1 gene that are associated with Progressive Myoclonic Epilepsy Type 7 (EPM7). This condition is a rare neurological disorder characterized by a combination of myoclonus (sudden, involuntary muscle jerks) and seizures, alongside other potential symptoms such as cognitive decline and ataxia. The test plays a crucial role in the accurate diagnosis and management of the disorder, allowing for targeted therapeutic strategies and genetic counseling for affected families.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and examining it for specific genetic alterations in the KCNC1 gene. These mutations disrupt the normal function of Kv3.1, a protein essential for the rapid firing of neurons, leading to the symptoms observed in EPM7.
The cost of the KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test is 4400 AED. Given the complexity of genetic testing and the specialized analysis involved, this cost reflects the comprehensive approach taken by DNA Labs UAE to ensure accurate and reliable results. For patients and families facing the challenges of Progressive Myoclonic Epilepsy Type 7, this test offers a valuable resource for diagnosis and future planning.
The SYN1 gene, associated with X-linked epilepsy accompanied by learning disabilities and behavioral disorders, is a critical area of genetic study. This condition manifests through a range of symptoms including seizures, cognitive challenges, and various behavioral issues due to mutations in the SYN1 gene, which plays a significant role in synaptic transmission in the brain. Understanding the genetic basis of these disorders can lead to more targeted and effective treatments.
At DNA Labs UAE, individuals can undergo a genetic test specifically designed to identify mutations in the SYN1 gene. This test is crucial for families seeking answers to unexplained symptoms of epilepsy, learning disabilities, and behavioral disorders that follow an X-linked inheritance pattern. Early diagnosis through genetic testing can significantly impact management strategies, allowing for personalized treatment plans that address both the neurological and behavioral aspects of the condition.
The cost of the SYN1 gene epilepsy genetic test at DNA Labs UAE is set at 4400 AED. This investment includes a comprehensive analysis aimed at detecting mutations within the SYN1 gene that are linked to the disorder. By choosing to undergo this test, individuals gain valuable insights into their genetic makeup, empowering them and their healthcare providers with the information needed to make informed decisions about their health and treatment options.
The KCNA1 Gene Episodic Ataxia Type 1 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the KCNA1 gene, which are linked to Episodic Ataxia Type 1 (EA1). EA1 is a rare genetic disorder characterized by brief episodes of ataxia, or lack of muscle coordination, often accompanied by myokymia (involuntary muscle twitching). These episodes can be triggered by stress, sudden movements, or physical exertion.
The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic alterations in the KCNA1 gene. Identifying these mutations can confirm a diagnosis of EA1, enabling targeted management and treatment strategies for affected individuals.
The cost of the KCNA1 Gene Episodic Ataxia Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the relevant genetic mutations, offering invaluable insights for patients and their families. By confirming a diagnosis, the test can facilitate informed decisions regarding treatment options, potential lifestyle adjustments, and genetic counseling for family planning.
The CACNB4 Gene Episodic Ataxia Type 5 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations in the CACNB4 gene, which are associated with Episodic Ataxia Type 5 (EA5). EA5 is a rare genetic disorder characterized by intermittent episodes of ataxia, or lack of voluntary coordination of muscle movements, including gait abnormality, as well as other potential symptoms such as vertigo, dysarthria, and nystagmus. The CACNB4 gene encodes a crucial subunit of the voltage-dependent calcium channel, playing a vital role in the proper functioning of neuronal cells. Mutations in this gene can disrupt calcium signaling, leading to the symptoms observed in EA5.
This genetic test is crucial for individuals exhibiting symptoms suggestive of episodic ataxia or for those with a family history of the condition, as it provides a definitive diagnosis by identifying the presence of specific mutations in the CACNB4 gene. Early and accurate diagnosis can aid in the management of symptoms and in making informed decisions regarding treatment and lifestyle adjustments.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the CACNB4 Gene Episodic Ataxia Type 5 Genetic Test is 4400 AED. The process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect mutations in the CACNB4 gene. Results from this test can provide valuable insights for patients and their families, guiding healthcare decisions and potentially improving quality of life for those affected by EA5.
The SLC1A3 Gene Episodic Ataxia Type 6 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the SLC1A3 gene, which are linked to Episodic Ataxia Type 6 (EA6). Episodic Ataxia is a neurological condition characterized by sudden attacks of ataxia (loss of control of body movements) along with other potential symptoms such as vertigo, dizziness, and headaches. EA6, a subtype of this condition, is specifically associated with mutations in the SLC1A3 gene.
This genetic test is crucial for individuals showing symptoms suggestive of EA6, as it helps in confirming the diagnosis, thereby enabling healthcare providers to tailor treatment and management plans more effectively. The procedure involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for the presence of mutations in the SLC1A3 gene.
The cost of the SLC1A3 Gene Episodic Ataxia Type 6 Genetic Test at DNA Labs UAE is set at 4400 AED. The test is conducted with high precision and accuracy, employing advanced genetic sequencing technologies to ensure reliable results. Given the specialized nature of this test and its significance in the accurate diagnosis and management of EA6, the investment is considered valuable for affected individuals and their families.
The SCN10A gene plays a crucial role in the human body by encoding the Nav1.8 sodium channel, which is essential for the transmission of pain signals in the peripheral nervous system. Mutations in the SCN10A gene can lead to episodic pain syndrome type 2, a familial condition characterized by recurrent episodes of severe pain without obvious physical causes. This condition underscores the importance of precise genetic diagnostics for individuals experiencing unexplained episodic pain.
The genetic test for episodic pain syndrome type 2, associated with the SCN10A gene, is a sophisticated diagnostic tool available at DNA Labs UAE. Priced at 4400 AED, this test offers individuals and families the opportunity to identify the genetic basis of their condition, paving the way for personalized management strategies and potential treatments. Conducted in a state-of-the-art facility, the test involves analyzing the patient's DNA to detect mutations in the SCN10A gene that are linked to the syndrome.
By opting for this genetic test, patients gain valuable insights into their condition, allowing for a more targeted approach to pain management and therapy. It also provides families with the information needed for genetic counseling, especially for those planning to have children and concerned about the hereditary nature of episodic pain syndrome type 2. DNA Labs UAE ensures confidentiality, accuracy, and support throughout the testing process, making it a trusted choice for genetic diagnostics in the region.
The SCN11A gene episodic pain syndrome type 3 familial genetic test is a specialized diagnostic procedure designed to identify mutations in the SCN11A gene, which are linked to the development of Familial Episodic Pain Syndrome Type 3 (FEPS3). This condition is characterized by episodes of severe pain without an apparent cause, affecting individuals from the same family, indicating a genetic basis. The SCN11A gene plays a crucial role in the transmission of pain signals in the nervous system, and mutations can lead to abnormal pain perception.
Conducted at DNA Labs UAE, a leading facility in genetic testing, this test offers a critical insight for affected individuals and their families, providing a definitive diagnosis of FEPS3. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed for specific genetic alterations in the SCN11A gene that are known to cause the syndrome.
The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results. Obtaining a diagnosis through this test can be pivotal for affected individuals, as it not only helps in understanding the cause of their pain but also guides the management and treatment strategies to mitigate the symptoms, improving their quality of life. Additionally, the results can inform family planning decisions for those carrying the mutation.
The SCN9A Gene Erythermalgia Primary Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the SCN9A gene, which are associated with Primary Erythermalgia (PE), also known as Primary Erythromelalgia. This rare condition is characterized by episodes of burning pain, redness, and swelling in the extremities, triggered by warm temperatures or mild physical activity. The test is crucial for confirming a clinical diagnosis of PE, enabling personalized treatment plans, and providing valuable information for family planning. Priced at 4400 AED, the test involves collecting a DNA sample, typically through a blood draw, and analyzing it for specific genetic mutations in the SCN9A gene. Results from this test can help in the management of symptoms and improve the quality of life for individuals with Primary Erythermalgia. DNA Labs UAE ensures a comprehensive and confidential testing process, guided by genetic counselors and medical professionals.
Ethylmalonic Encephalopathy (EE) is a rare genetic disorder characterized by progressive neurological impairment, metabolic abnormalities, and, in many cases, early mortality. The condition is caused by mutations in the ETHE1 gene, which plays a crucial role in the metabolic process. The disorder manifests with a range of symptoms including developmental delay, seizures, chronic diarrhea, and orthostatic acrocyanosis, making early and accurate diagnosis vital for management and treatment planning.
The ETHE1 Gene Ethylmalonic Encephalopathy Genetic Test is a specialized diagnostic tool designed to detect mutations in the ETHE1 gene, confirming the diagnosis of EE. This test is critical for families with a history of the disorder or where EE is suspected based on clinical symptoms. Early diagnosis through genetic testing can facilitate timely intervention and potentially improve outcomes.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers a comprehensive analysis of the ETHE1 gene. DNA Labs UAE employs state-of-the-art technology and adheres to stringent quality control measures to ensure the accuracy and reliability of test results. The cost of the ETHE1 Gene Ethylmalonic Encephalopathy Genetic Test is 4400 AED, reflecting the advanced nature of the testing process and the specialized expertise required to interpret the results.
Families and individuals undergoing this test at DNA Labs UAE can expect professional guidance throughout the testing process, from sample collection to result interpretation. The facility's genetic counselors are available to discuss the implications of test outcomes and support patients in making informed decisions about their health and management options.
The ATP1A2 gene plays a crucial role in the proper functioning of brain cells. Mutations in this gene are associated with familial hemiplegic migraine type 2 (FHM2), a rare form of migraine characterized by severe headache accompanied by temporary paralysis on one side of the body (hemiplegia), sensory disturbances, and, in some cases, coma or seizure-like episodes. These symptoms are much more severe than those of a typical migraine.
To diagnose this condition accurately, genetic testing is available at DNA Labs UAE, which specifically looks for mutations in the ATP1A2 gene. This test is vital for individuals with a family history of FHM2 or those who exhibit symptoms suggestive of this condition. By identifying mutations in the ATP1A2 gene, healthcare providers can confirm a diagnosis of familial hemiplegic migraine type 2, which can significantly aid in the management and treatment of the condition.
The cost of the ATP1A2 gene familial hemiplegic migraine type 2 genetic test at DNA Labs UAE is 4400 AED. This comprehensive test is conducted by healthcare professionals who specialize in genetic testing, ensuring accurate and reliable results. Opting for this test at DNA Labs UAE not only provides individuals with a definitive diagnosis but also helps in understanding the genetic basis of their condition, which is crucial for making informed decisions about treatment and management.
